Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Brand Name :
Pulmoza
Synonyms :
ozagrel hydrochloride
Class :
Thromboxane A2 synthesis inhibitor
Dosage forms and strengths Â
Oral tablet Â
100 mgÂ
200 mgÂ
Powder for injection Â
40 mg Â
80 mgÂ
In vivo, data suggests taking one tablet of 200 mg two times daily after the morning meal & prior to sleep
Not indicatedÂ
Refer adult dosingÂ
Actions and Spectrum:Â
Action:Â
ozagrel hydrochloride has been demonstrated to lessen bronchial hyperresponsiveness to acetylcholine and leukotriene D4.Â
Frequency not defined Â
Abdominal discomfortÂ
Gastric discomfortÂ
DizzinessÂ
SleepinessÂ
Allergic reactionsÂ
Black Box Warning:Â Â
None
Contraindication/Caution:Â Â
Allergy: ozagrel hydrochloride is contraindicated if the patient is allergic to the drug or any component of the drug.Â
Pregnancy and breast-feeding:Â It should not be given to pregnant or breastfeeding women. There is a lack of comprehensive data on the use of ozagrel hydrochloride during pregnancy and lactation.Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology: ozagrel hydrochloride belongs to a class of thromboxane A2 synthase inhibitors.Â
Pharmacodynamics:Â Â
It works by suppressing the production of thromboxane A2, a substance that contributes to vasoconstriction and platelet aggregation. This action contributes to its antiplatelet and vasodilatory effects. Â
Pharmacokinetics:Â
AbsorptionÂ
ozagrel hydrochloride is absorbed in the gastrointestinal tract after oral administration.Â
DistributionÂ
It distributes throughout the body, with a significant portion binding to plasma proteins.Â
MetabolismÂ
The metabolism of ozagrel hydrochloride involves various enzymatic processes in the liver.Â
Excretion and EliminationÂ
ozagrel and its metabolites are mainly excreted through urinary mode.Â
Â
Administration: Â
Ask the healthcare provider before using the drug for dosage frequency and condition treated.Â
The preferred route of administration is oral.Â
Patient information leafletÂ
Generic Name: ozagrel hydrochlorideÂ
Why do we use ozagrel hydrochloride? Â
ozagrel hydrochloride is used to treat movement disorders linked to acute phase cerebral thrombosis and cerebrovascular spasms, which are signs of cerebral ischemia that occur following surgery for subarachnoid haemorrhage.Â